These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 37444422)

  • 1. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
    Lo JH; Agarwal R; Goff LW; Heumann TR
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
    Wilbur HC; Azad NS
    Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date.
    Storandt MH; Jin Z; Mahipal A
    Onco Targets Ther; 2024; 17():383-394. PubMed ID: 38774819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
    Kang S; El-Rayes BF; Akce M
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    Merters J; Lamarca A
    J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.
    Wheless M; Agarwal R; Goff L; Lockney N; Padmanabhan C; Heumann T
    Curr Treat Options Oncol; 2024 Jan; 25(1):127-160. PubMed ID: 38177560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapies for Advanced Biliary Tract Cancer.
    Zeng W; Mao R; Zhang Z; Chen X
    J Clin Transl Hepatol; 2023 Apr; 11(2):490-501. PubMed ID: 36643047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma.
    Kawamura E; Matsubara T; Kawada N
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.
    Palmieri LJ; Lavolé J; Dermine S; Brezault C; Dhooge M; Barré A; Chaussade S; Coriat R
    Pharmacol Ther; 2020 Jun; 210():107517. PubMed ID: 32109491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs).
    Han S; Lee SY; Wang WW; Tan YB; Sim RHZ; Cheong R; Tan C; Hopkins R; Connolly J; Shuen WH; Toh HC
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic Approaches to Biliary Cancer.
    Shah UA; Nandikolla AG; Rajdev L
    Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.
    Malenica I; Donadon M; Lleo A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.